Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetShares Repurchased
Ratios

BridgeBio Pharma (BBIO) Long-Term Debt Issuances (2019 - 2025)

BridgeBio Pharma's Long-Term Debt Issuances history spans 5 years, with the latest figure at $575.0 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $575.0 million; the TTM value through Dec 2025 reached $575.0 million, up 27.78%, while the annual FY2025 figure was $575.0 million, 27.78% up from the prior year.
  • Long-Term Debt Issuances for Q4 2025 was $575.0 million at BridgeBio Pharma, up from -$575.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $747.5 million in Q1 2021 and bottomed at -$575.0 million in Q3 2025.
  • The 3-year median for Long-Term Debt Issuances is $575.0 million (2025), against an average of $354.5 million.
  • The largest annual shift saw Long-Term Debt Issuances soared 35.91% in 2021 before it crashed 227.78% in 2025.
  • A 3-year view of Long-Term Debt Issuances shows it stood at $747.5 million in 2021, then tumbled by 39.8% to $450.0 million in 2024, then grew by 27.78% to $575.0 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Long-Term Debt Issuances are $575.0 million (Q4 2025), -$575.0 million (Q3 2025), and $575.0 million (Q1 2025).